Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate

依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯

Report date: 2025/05/15 20:00:08

Base Information

Drug NameEfavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Drug Alias Name富马酸替诺福韦二吡呋酯/恩曲他滨/依非韦伦Tenofovir Disoproxil Fumarate/Emtricitabine/EfavirenzEmtricitabine/Efavirenz/Tenofovir Disoproxil Fumarate恩曲他滨/依非韦伦/富马酸替诺福韦二吡呋酯/依非韦伦+恩曲他滨+替诺福韦二吡呋酯 +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/07/12
Country/TerritoryUnited StatesEU
CombinationsYes EfavirenzEmtricitabineTenofovir Disoproxil Fumarate
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGilead IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncGilead Sciences Ireland Uc
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeJ05AR06
Related LinksWikipediaKEGG